Pascal Urwyler Stephan Moser Panteleimon Charitos Ingmar A F M Heijnen Melanie Rudin Gregor Sommer Bruno M Giannetti Stefano Bassetti Parham Sendi Marten Trendelenburg Michael Osthoff
10.3389/fimmu.2020.02072
Front Immunol
2020 Aug 14;11:2072.
c1 esterase inhibitor covid-19 sars-cov-2 complement system contact activation system inflammation kallikrein-kinin system
CC BY
https://pubmed.ncbi.nlm.nih.gov/32922409/
Betacoronavirus / drug effects Complement C1 / antagonists & inhibitors Complement C1 Inhibitor Protein / therapeutic use Coronavirus Infections / drug therapy Cytokine Release Syndrome / drug therapy Kallikrein-Kinin System / drug effects Pneumonia, Viral / drug therapy
Betacoronavirus / drug effects Complement C1 / antagonists & inhibitors Complement C1 Inhibitor Protein / therapeutic use Coronavirus Infections / drug therapy Cytokine Release Syndrome / drug therapy Kallikrein-Kinin System / drug effects Pneumonia, Viral / drug therapy Aged Aged, 80 and over COVID-19 Complement C1 Inhibitor Protein / analysis Factor XIa / antagonists & inhibitors Female Humans Kallikreins / antagonists & inhibitors Male Middle Aged Pandemics Recombinant Proteins / therapeutic use SARS-CoV-2 Viral Load / drug effects Complement C1 Complement C1 Inhibitor Protein Recombinant Proteins SERPING1 protein, human conestat alfa Kallikreins Factor XIa
PMC7456998
32922409
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
2020